# ALTA-3 (NCT03596866)

> A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

No report yet. It can be ordered.

- Indication: crizotinib-resistant advanced ALK-positive NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03596866
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: ALK+ Advanced NSCLC
- Interventions: Brigatinib; Alectinib
- Enrollment: 248
- Primary outcome: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1

## Indexed commentary on ALTA-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=alta-3-nct03596866